Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-12
2011-07-12
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S303000, C514S253040, C544S362000, C546S119000
Reexamination Certificate
active
07977325
ABSTRACT:
This invention relates to compounds of general formula Iin which R1and R2are described in this application, the use of the compounds of general formula I as inhibitors of protein tyrosine kinases for treatment of various diseases as well as the compounds of general formulas II and IIIas intermediate compounds for the production of compounds of general formula I, wherein X, R1aand R2ahave the meaning that is described in general formulas II and III.
REFERENCES:
patent: 4182887 (1980-01-01), Roch et al.
patent: 4224322 (1980-09-01), Roch et al.
patent: 4260621 (1981-04-01), Roch et al.
patent: 4366231 (1982-12-01), Mayer et al.
patent: 5478830 (1995-12-01), Higley et al.
patent: 6046216 (2000-04-01), Piazza et al.
patent: 6562811 (2003-05-01), Murata et al.
patent: 2004/0014784 (2004-01-01), Jakobi et al.
patent: 2004/0255397 (2004-12-01), Fessmann et al.
patent: 2160780 (1973-06-01), None
patent: 2238400 (1974-02-01), None
patent: 2355967 (1975-07-01), None
patent: 2643753 (1978-04-01), None
patent: 3001498 (1981-07-01), None
patent: 1308441 (2003-05-01), None
patent: WO 01/19828 (2001-03-01), None
patent: WO 03/008405 (2003-01-01), None
patent: WO 03008405 (2003-01-01), None
Jordan, V.C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dorwald F. Zaragoza. Side Reviews in Organic Synthesis: A guide to successful synthesis design, Weinheim: WILEY-VCH, Verlag, GMBH & Co. KGaA, 2005. Preface.
Wolff et al. Burger's Medicinal Chemistry and Drug Discovery—Fifth edition, New York: John Wiley & Sons, 1006, vol. 1 pp. 975-976.
Kaupp., G. et al., European Journal of Organic Chemistry, 2003, pp. 1545-1551, No. 8.
Gamal, A., Zagazig Journal of Pharmaceutical Sciences, 1994, pp. 148-153, vol. 3, No. 2.
Kalme, Z. A. et al., Khimiya Geterotsiklicheskikh Soedinenii, 1992, pp. 1218-1222, No. 9.
El-Dean, A. M. Kamal et al., Bulletin of the Faculty of Science, 1991, Assiut University, pp. 15-21, vol. 20, No. 1. or Ei-Dean, A. M. et al., Indian Journal of Chemistry, 1991, pp. 878-882, vol. 30B, No. 9.
Gamal et al., Journal of Saudi Chemical Society, 2001, pp. 183-187, vol. 5, No. 2.
Mohamed, A. et al., Phosphorus, Sulfur and Silicon, 2000, pp. 161-179, vol. 167.
Attaby, Fawzy A. et al., Phosphorus, Sulfur and Silicon, 1999, pp. 49-64, vol. 149.
Attaby, Fawzy A. et al., Phosphorus, Sulfur and Silicon, 1999, pp. 253-270, vol. 155.
Sanna, Eldin M. et al., Egyptian Journal of Pharmaceutical Sciences, 1998, pp. 197-209, vol. 39, No. 1-3.
Arustamova, I. S. et al., Chemistry of Heterocyclic Compounds, 1999, pp. 58-63, vol. 35, No. 1.
Lacan, M. and Tabakovic K., Chroatica Chemica Acta, 1975, pp. 127-133, vol. 47, No. 2.
Chandra, Sheker Reddy et al., Journal of Fluorine Chemistry, 1997, pp. 127-130, vol. 86, No. 2.
Abdel, Hafez et al., Collection of Czechoslovak Chemical Communications, 1993, pp. 1198-1202, vol. 58, No. 5.
Deeb, Ali, Collection of Czechoslovak Chemical Communications, 1991, pp. 1560-1563, vol. 56, No. 7.
Gohar, Abdel Kerim et al., Archiv der Pharmazie, 1987, Weinheim, Germany, pp. 823-829, vol. 320, No. 9.
Balicki, R. et al., Polish Journal of Chemistry, 1979, pp. 1515-1525, vol. 53, No. 7-8.
Pejcic, Marijan et al., Acta Pharmaceutica Jugoslavia, 1977, pp. 143-146, vol. 27, No. 3.
Bomika, Z. et al., Khimiya Geterotsiklicheskikh Soedinenii, 1976, pp. 1085-1088, No. 8.
Yoshida, Kei et al., Yakugaku Zasshi, 1976, pp. 33-36, vol. 96, No. 1.
F. E. Goda et al., Bioorganic & Medicinal Chemistry, 2004, pp. 1845-1852, vol. 12, No. 8.
B. Narsaiah et al., Journal of Fluorine Chemistry, 2001, pp. 183-187, vol. 109.
Database Registry, Jul. 10, 2002, XP002373925, Database accession No. RN:438020-37-2, 6-cyclopropyl-4-(4-methoxyphenyl)-1H-Pyrazolo[3,4-b]pyridin-3-amine, Supplier: Ambinter, Summary.
Murata et al., “Discovery of novel and selective IKK-? Serine-threonine protein kinase inhibitors. Part 1” Bioorganic & Medicinal Chemistry Letters, vol. 13, No. 5, 2003, pp. 913-918, XP002373853.
Database Chemcats, Jan. 18, 2005, Interchim Intermediates: XP002373926, Database accession No. 2005:1815941, Chemcats, 4-cyclopropyl-6-(trifluoromethyl)-1H-Pyrazolo[3,4,-b]pyridin-3-amine CAS Registry No. (RN): 832739-88-5, Summary.
Bader Benjamin
Hillig Roman
Kuenzer Hermann
Moenning Ursula
Schmitz Arndt
Bayer Schering Pharma AG
Fetterolf Brandon J
Millen White Zelano & Branigan P.C.
Pagonakis Anna
LandOfFree
3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2718263